Valneva (VALN) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Valneva SE is initiating a private placement of approximately 60 million euros worth of new ordinary shares to fund its vaccine development programs, including clinical trials for chikungunya, Shigella, and Zika vaccines, and to further commercialize its chikungunya vaccine IXCHIQ®. The company is offering the shares at a discounted price and expects to use the proceeds to support its growth and operational business until milestone revenues from its Lyme disease program contribute to profitability. This financing strategy is aimed at strengthening Valneva’s financial position as it advances its pipeline of vaccine candidates.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
